TK
Takuya Kijima
About Takuya Kijima
Data last updated:
Takuya Kijima is an Additional Director at Eisai Pharmaceuticals India Private Limited (since 2025). The company operates in Pharma. Eisai Pharmaceuticals India Private Limited reported revenue of ₹402 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Eisai Pharmaceuticals India Private Limited U21002AP2007PTC053247 | Additional Director | 17 Oct 2025 | 2007 | ₹402 Cr (FY 2025) | Active |
Board colleagues of Takuya Kijima
| Name | DIN | Company | Designation |
|---|---|---|---|
| Akiko Nakahama | 11141964 | Eisai Pharmaceuticals India Private Limited | Director |
| Girish Dixit | 08591725 | Eisai Pharmaceuticals India Private Limited | Director |
| Kentaro Nagane | 10526897 | Eisai Pharmaceuticals India Private Limited | Director |
| Masahito Suzuki | 11142062 | Eisai Pharmaceuticals India Private Limited | Director |
| Mitsuru Shomon | 09299363 | Eisai Pharmaceuticals India Private Limited | Director |
| Shohei Kanazawa | 08760183 | Eisai Pharmaceuticals India Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Takuya Kijima
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Takuya Kijima
Takuya Kijima currently holds 1 directorship: Eisai Pharmaceuticals India Private Limited (Additional Director, since 17 Oct 2025, revenue ₹402 Cr (FY 2025)).
Takuya Kijima was first appointed on 17 Oct 2025 as Additional Director at Eisai Pharmaceuticals India Private Limited.
The current boards of Takuya Kijima's companies include Akiko Nakahama (Eisai Pharmaceuticals India Private Limited), Girish Dixit (Eisai Pharmaceuticals India Private Limited), Kentaro Nagane (Eisai Pharmaceuticals India Private Limited), Masahito Suzuki (Eisai Pharmaceuticals India Private Limited), Mitsuru Shomon (Eisai Pharmaceuticals India Private Limited), Shohei Kanazawa (Eisai Pharmaceuticals India Private Limited).